ArticleEClinicalMedicine2022

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.

Keiko Imamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.